Stock & Company Details
Hemab Therapeutics Holdings $COAG
Price:
N/A
N/A
N/A
$1.8B
52 Week High:
N/A
10 Day Average Volume:
N/A
N/A
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
N/A
COAG technical indicators
Latest Hemab Therapeutics Holdings (COAG) indicator readings as of 2026-10-29.
COAG's 14-day RSI is 65.2, in neutral territory. Price sits above the upper Bollinger Band ($26.17 to $39.65). ADX reads 28.7, indicating a trending market.
Overview
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
Finance Bot
Ask your questions
Start by typing a question below.
